Anthracyclines in breast cancer: therapy and issues of toxicity
- 30 June 2001
- journal article
- Published by Elsevier in The Breast
- Vol. 10, 8-15
- https://doi.org/10.1016/s0960-9776(01)80002-3
Abstract
No abstract availableThis publication has 34 references indexed in Scilit:
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-upNew England Journal of Medicine, 1995
- Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast CarcinomaNew England Journal of Medicine, 1994
- Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicityCancer Treatment Reviews, 1993
- Pharmacokinetics of the Cardioprotector ADR-529 (ICRF-187) in Escalating Doses Combined With Fixed-Dose DoxorubicinJNCI Journal of the National Cancer Institute, 1992
- “Classical” CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer: An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)European Journal of Cancer and Clinical Oncology, 1991
- Protective Effect of the Bispiperazinedione ICRF-187 against Doxorubicin-Induced Cardiac Toxicity in Women with Advanced Breast CancerNew England Journal of Medicine, 1988
- Iron(III)-adriamycin and iron(III)-daunorubicin complexes: physicochemical characteristics, interaction with DNA, and antitumor activityBiochemistry, 1985
- Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase IIScience, 1984
- Mechanism of adriamycin cardiotoxicity: Evidence for oxidative stressLife Sciences, 1981